Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23611755 | 1.00 | ALOX15 (0.47) | ALOX15HSD17B10HPGDTP53GLA | |
| SCHEMBL23611738 | 0.92 | ALOX15 (0.44) | ALOX15HSD17B10TP53ALDH1A1GAA | |
| SCHEMBL23623267 | 0.92 | TP53 (0.42) | ALOX15HSD17B10HPGDTP53GLA | |
| SCHEMBL23611711 | 0.91 | ADORA3 (0.41) | ALOX15HSD17B10HPGDTP53GLA | |
| SCHEMBL23758245 | 0.91 | MAPT (0.43) | ALOX15HSD17B10HPGDTP53GLA | |
| SCHEMBL23623309 | 0.91 | ALOX15 (0.43) | ALOX15HSD17B10TP53POLBALDH1A1 | |
| SCHEMBL23623437 | 0.90 | HPGD (0.45) | HSD17B10HPGDTP53POLBALDH1A1 | |
| SCHEMBL23611718 | 0.89 | SMN1; SMN2 (0.43) | HSD17B10HPGDPOLBALDH1A1ADORA2A | |
| SCHEMBL23611728 | 0.89 | ALOX15 (0.43) | ALOX15HSD17B10HPGDPOLBADORA2A | |
| SCHEMBL23611737 | 0.89 | POLB (0.39) | ALOX15HSD17B10HPGDTP53GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694886-A1 | MICROTUBULE TARGETING AGENTS | BPGbio, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250017906-A1 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | BERG, KARA ANN | 2025-01-16 | — | — | US | claimed |
| WO-2024216283-A1 | MICROTUBULE TARGETING AGENTS | BPGBIO, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| US-20240342138-A1 | MICROTUBULE TARGETING AGENTS | THLIVERIS, ANDREW T. | 2024-10-17 | — | — | US | claimed |
| EP-4433051-A1 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | BPGbio, Inc. (US) | 2024-09-25 | — | — | EP | claimed |
| CN-118488837-A | Compounds for the treatment of gastric cancer | 布普格生物制药公司 | 2024-08-13 | — | — | CN | claimed |
| WO-2023091590-A1 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | BERG LLC (US) | 2023-05-25 | — | — | WO | claimed |
| EP-4694886-A1 | MICROTUBULE TARGETING AGENTS | BPGbio, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4694886-A1 | MICROTUBULE TARGETING AGENTS | BPGbio, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| CN-121398816-A | Microtubule targeting agents | 布普格生物制药公司 | 2026-01-23 | — | — | CN | disclosed |
| US-20250017906-A1 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | BERG, KARA ANN | 2025-01-16 | — | — | US | disclosed |
| WO-2024216283-A1 | MICROTUBULE TARGETING AGENTS | BPGBIO, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024216283-A1 | MICROTUBULE TARGETING AGENTS | BPGBIO, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240342138-A1 | MICROTUBULE TARGETING AGENTS | THLIVERIS, ANDREW T. | 2024-10-17 | — | — | US | disclosed |
| US-20240342138-A1 | MICROTUBULE TARGETING AGENTS | THLIVERIS, ANDREW T. | 2024-10-17 | — | — | US | disclosed |
| EP-4433051-A1 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | BPGbio, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118488837-A | Compounds for the treatment of gastric cancer | 布普格生物制药公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023091590-A1 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | BERG LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-4085056-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | Berg LLC (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-115210229-A | Polycyclic amides as UBE2K modulators for the treatment of cancer | 博格有限责任公司 | 2022-10-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017906-A1 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | PGC, FABP6, GIPR | ALOX15 604/4885HSD17B10 1248/4885HPGD 89/4885 |
| US-20240342138-A1 | MICROTUBULE TARGETING AGENTS | MAP2, TUBB3, TUBB1 | ALOX15 4881/4885HSD17B10 4513/4885HPGD 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.